Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.53 |
| ▸ | KDR | P35968 | 11/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1707259 | 0.93 | EGFR (0.49) | EGFRKDRLRRK2RETFLT1 | |
| SCHEMBL1706570 | 0.92 | KDR (0.53) | EGFRKDREPHA2LRRK2RET | |
| SCHEMBL3399657 | 0.90 | EGFR (0.51) | EGFRKDREPHA2ERBB2ERBB4 | |
| SCHEMBL1706625 | 0.88 | EGFR (0.46) | EGFRKDRLRRK2RET | |
| SCHEMBL1706613 | 0.88 | EGFR (0.59) | EGFRKDRERBB2LRRK2RET | |
| SCHEMBL1707039 | 0.87 | EGFR (0.45) | EGFRKDRERBB2LRRK2RET | |
| SCHEMBL1708497 | 0.85 | NSD2 (0.49) | EGFRKDRLRRK2RET | |
| SCHEMBL1838804 | 0.85 | KDR (0.58) | EGFRKDREPHA2ERBB2LRRK2 | |
| SCHEMBL1706533 | 0.85 | EGFR (0.45) | EGFRKDRLRRK2RET | |
| SCHEMBL1706719 | 0.85 | KDR (0.58) | EGFRKDREPHA2ERBB2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863283-B2 | Sulphoximine-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2011-01-04 | — | — | US | claimed |
| EP-2247579-B1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNOMODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | Bayer Pharma AG (DE) | 2012-04-18 | — | — | EP | disclosed |
| EP-2247579-B1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNOMODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | Bayer Pharma AG (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-7863283-B2 | Sulphoximine-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2011-01-04 | — | — | US | disclosed |
| US-7863283-B2 | Sulphoximine-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2011-01-04 | — | — | US | disclosed |
| EP-2247579-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNOMODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009089851-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNOMODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-23 | — | — | WO | disclosed |
| US-20090186911-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| WO-2009089851-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNOMODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-23 | — | — | WO | disclosed |
| US-20090186911-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186911-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | IFNG, TPMT, IRF3 | EGFR 4536/4885KDR 3554/4885EPHA2 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.